• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.针对伴有TET2突变的慢性粒单核细胞白血病患者的大剂量静脉注射维生素C疗法。
Blood. 2024 Dec 5;144(23):2456-2461. doi: 10.1182/blood.2024024962.
2
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.贝克斯马里单抗联合阿扎胞苷治疗高危骨髓增生异常综合征及复发或难治性急性髓系白血病：一项多中心、单臂、1/2期试验剂量递增部分的结果
Lancet Haematol. 2025 May 28. doi: 10.1016/S2352-3026(25)00103-6.
3
[Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy].[新诊断的伴过多原始细胞的骨髓增生异常综合征患者接受去甲基化药物治疗前后基因突变状态与治疗疗效及生存的相关性分析]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):417-424. doi: 10.3760/cma.j.cn121090-20241210-00553.
4
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.伴 TET2 和 IDH1/2 突变的骨髓增生异常综合征中的克隆性白血病演变。
Haematologica. 2014 Jan;99(1):28-36. doi: 10.3324/haematol.2013.091249. Epub 2013 Aug 30.
5
TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.TET2 突变和高 miR-22 表达作为预测接受低甲基化治疗的骨髓增生异常综合征患者临床结局的生物标志物。
Curr Issues Mol Biol. 2021 Aug 5;43(2):917-931. doi: 10.3390/cimb43020065.
6
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.鲁卡帕尼对比化疗治疗携带有害BRCA1或BRCA2突变的复发性卵巢癌（ARIEL4）：一项国际、开放标签、随机、3期试验的最终结果
Lancet Oncol. 2025 Feb;26(2):249-264. doi: 10.1016/S1470-2045(24)00674-0.
7
Consequences of mutant TET2 on clonality and subclonal hierarchy.突变型 TET2 对克隆性和亚克隆层次结构的影响。
Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.
8
Thrombopoietin mimetics for patients with myelodysplastic syndromes.用于骨髓增生异常综合征患者的血小板生成素模拟物。
Cochrane Database Syst Rev. 2017 Sep 30;9(9):CD009883. doi: 10.1002/14651858.CD009883.pub2.
9
Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison.慢性粒单核细胞白血病进展的克隆动力学：配对样本比较
J Pathol. 2025 Apr;265(4):437-447. doi: 10.1002/path.6396. Epub 2025 Feb 5.
10
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.TET2功能的恢复可阻断异常自我更新和白血病进展。
Cell. 2017 Sep 7;170(6):1079-1095.e20. doi: 10.1016/j.cell.2017.07.032. Epub 2017 Aug 17.

引用本文的文献

1
Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.靶向实践：CHIP和CCUS中的治疗干预机会。
Blood Rev. 2025 Jul 25:101323. doi: 10.1016/j.blre.2025.101323.
2
Management of Myeloproliferative Neoplasms: An Integrative Approach.骨髓增殖性肿瘤的管理：一种综合方法。
J Clin Med. 2025 Jul 17;14(14):5080. doi: 10.3390/jcm14145080.
3
The physiological functions of ascorbate in the development of cancer.抗坏血酸盐在癌症发展中的生理功能。
Dis Model Mech. 2025 Apr 1;18(4). doi: 10.1242/dmm.052201. Epub 2025 Apr 11.
4
[The state of the art: diagnosis and therapeutic interventions of clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance].[最新进展：意义未明的克隆性造血和意义未明的克隆性血细胞减少症的诊断与治疗干预]
Zhonghua Xue Ye Xue Za Zhi. 2025 Jan 14;46(1):5-8. doi: 10.3760/cma.j.cn121090-20241228-00600.
5
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.克隆性造血中治疗干预及早期临床试验的开展蓝图。
Br J Haematol. 2025 Feb;206(2):416-427. doi: 10.1111/bjh.19925. Epub 2024 Dec 9.

本文引用的文献

1
Risk prediction for clonal cytopenia: multicenter real-world evidence.克隆性血细胞减少症的风险预测：多中心真实世界证据。
Blood. 2024 Nov 7;144(19):2033-2044. doi: 10.1182/blood.2024024756.
2
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms.第五版《世界卫生组织造血与淋巴组织肿瘤分类》：髓系肿瘤。
Mod Pathol. 2024 Feb;37(2):100397. doi: 10.1016/j.modpat.2023.100397. Epub 2023 Dec 1.
3
Prediction of risk for myeloid malignancy in clonal hematopoiesis.克隆性造血中髓系恶性肿瘤风险的预测
NEJM Evid. 2023 May;2(5). doi: 10.1056/evidoa2200310. Epub 2023 Apr 25.
4
Vitamin C boosts DNA demethylation in TET2 germline mutation carriers.维生素 C 可增强 TET2 种系突变携带者的 DNA 去甲基化。
Clin Epigenetics. 2023 Jan 14;15(1):7. doi: 10.1186/s13148-022-01404-6.
5
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
6
ReMap 2022: a database of Human, Mouse, Drosophila and Arabidopsis regulatory regions from an integrative analysis of DNA-binding sequencing experiments.ReMap 2022：一个整合了 DNA 结合测序实验分析的人类、小鼠、果蝇和拟南芥调控区域数据库。
Nucleic Acids Res. 2022 Jan 7;50(D1):D316-D325. doi: 10.1093/nar/gkab996.
7
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients.CCUS与低风险骨髓增生异常综合征之间的临床、分子及预后比较：一项对187例分子注释患者的研究
Blood Adv. 2021 Apr 27;5(8):2272-2278. doi: 10.1182/bloodadvances.2020003976.
8
Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study.意义未明的克隆性血细胞减少症的治疗结果：一项单机构回顾性研究。
Blood Cancer J. 2021 Mar 1;11(3):43. doi: 10.1038/s41408-021-00439-x.
9
Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate.新兴的表观遗传学疗法治疗髓性白血病：用抗坏血酸调节去甲基化酶活性。
Haematologica. 2021 Jan 1;106(1):14-25. doi: 10.3324/haematol.2020.259283.
10
LRF/ZBTB7A conservation accentuates its potential as a therapeutic target for the hematopoietic disorders.LRF/ZBTB7A 的保守性突出了其作为造血系统疾病治疗靶点的潜力。
Gene. 2020 Nov 15;760:145020. doi: 10.1016/j.gene.2020.145020. Epub 2020 Aug 2.

针对伴有TET2突变的慢性粒单核细胞白血病患者的大剂量静脉注射维生素C疗法。

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.

作者信息

Xie Zhuoer, Fernandez Jenna, Lasho Terra, Finke Christy, Amundson Michelle, McCullough Kristen B, LaPlant Betsy R, Mangaonkar Abhishek A, Gangat Naseema, Reichard Kaaren K, Elliott Michelle, Witzig Thomas E, Patnaik Mrinal M

机构信息

Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.

出版信息

Blood. 2024 Dec 5;144(23):2456-2461. doi: 10.1182/blood.2024024962.

DOI:10.1182/blood.2024024962
PMID:39352751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628862/
Abstract

This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.gov as #NCT03418038.

摘要

这项2期试验评估了高剂量静脉注射抗坏血酸治疗TET2突变克隆性血细胞减少症的效果。10名患者中有8名符合反应评估条件，根据国际骨髓增生异常综合征/肿瘤工作组标准，在第20周时未出现反应。该试验已在www.clinicaltrials.gov上注册，注册号为#NCT03418038。